Piperacillin-tazobactam As Alternative to Carbapenems for ICU Patients

Overview

Journal Ann Intensive Care

Specialty Critical Care

Date 2017 Nov 12

PMID 29127502

Citations 14

Authors

Benoit Pilmis

Vincent Jullien

Alexis Tabah

Jean-Ralph Zahar

Christian Brun-Buisson

Affiliations

Soon will be listed here.

Abstract

Several studies suggest that alternatives to carbapenems, and particulary beta-lactam/beta-lactamase inhibitor combinations, can be used for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-related infections in non-ICU patients. Little is known concerning ICU patients in whom achieving the desired plasmatic pharmacokinetic/pharmacodynamic (PK/PD) target may be difficult. Also, in vitro susceptibility to beta-lactamase inhibitors might not translate into clinical efficacy. We reviewed the recent clinical studies examining the use of BL/BLI as alternatives to carbapenems for therapy of bloodstream infection, PK/PD data and discuss potential ecological benefit from avoiding the use of carbapenems. With the lack of prospective randomized studies, treating ICU patients with ESBL-PE-related infections using piperacillin-tazobactam should be done with caution. Current data suggest that BL/BLI empirical use should be avoided for therapy of ESBL-PE-related infection. Also, definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests. Optimization of administration and higher dosage should be used in order to reach pharmacological targets.

Citing Articles

Antibiotic susceptibility patterns at the Médecins Sans Frontières (MSF) Acute Trauma Hospital in Aden, Yemen: a retrospective study from January 2018 to June 2021.

Almehdar H, Yousef N, van den Boogaard W, Haider A, Kanapathipillai R, Al-Hodiani E JAC Antimicrob Resist. 2024; 6(2):dlae024.

PMID: 38449518 PMC: 10914454. DOI: 10.1093/jacamr/dlae024.

ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali.

Kalambry A, Potindji T, Guindo I, Kassogue A, Drame B, Togo S Drug Target Insights. 2023; 17:92-100.

PMID: 37654725 PMC: 10466504. DOI: 10.33393/dti.2023.2613.

Evaluation of the synergistic effect of chitosan metal ions (Cu/Co) in combination with antibiotics to counteract the effects on antibiotic resistant bacteria.

Elbialy N, Elhakim H, Mohamed M, Zakaria Z RSC Adv. 2023; 13(26):17978-17990.

PMID: 37323456 PMC: 10265139. DOI: 10.1039/d3ra02758a.

Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study.

Cariou E, Griffier R, Orieux A, Silva S, Faguer S, Seguin T Ann Intensive Care. 2023; 13(1):22.

PMID: 36959425 PMC: 10036246. DOI: 10.1186/s13613-023-01106-z.

Comparative effectiveness of antibiotic therapy for carbapenem-resistant Enterobacterales (CRE) bloodstream infections in hospitalized US veterans.

Wilson G, Fitzpatrick M, Suda K, Smith B, Gonzalez B, Jones M JAC Antimicrob Resist. 2022; 4(5):dlac106.

PMID: 36320448 PMC: 9596539. DOI: 10.1093/jacamr/dlac106.

References

Prinapori R, Guinaud J, Khalil A, Lecuyer H, Gendrel D, Lortholary O . Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae. Am J Infect Control. 2012; 41(3):259-60. DOI: 10.1016/j.ajic.2012.03.035. View

Ling M, Tee Y, Tan S, Amin I, How K, Tan K . Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015; 4:26. PMC: 4477303. DOI: 10.1186/s13756-015-0066-3. View

De Rosa F, Pagani N, Fossati L, Raviolo S, Cometto C, Cavallerio P . The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection. 2011; 39(6):555-61. DOI: 10.1007/s15010-011-0201-x. View

Orsi G, Bencardino A, Vena A, Carattoli A, Venditti C, Falcone M . Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection. 2012; 41(1):61-7. DOI: 10.1007/s15010-012-0354-2. View

Paterson D, Ko W, von Gottberg A, Mohapatra S, Casellas J, Goossens H . Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39(1):31-7. DOI: 10.1086/420816. View

Sader H, Farrell D, Flamm R, Jones R . Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014; 43(4):328-34. DOI: 10.1016/j.ijantimicag.2014.01.007. View

Pettigrew M, Johnson J, Harris A . The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Ann Epidemiol. 2016; 26(5):342-7. PMC: 4892961. DOI: 10.1016/j.annepidem.2016.02.007. View

Balakrishnan I, Awad-El-Kariem F, Aali A, Kumari P, Mulla R, Tan B . Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011; 66(11):2628-31. DOI: 10.1093/jac/dkr317. View

Harris P, Tambyah P, Paterson D . β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis. 2015; 15(4):475-85. DOI: 10.1016/S1473-3099(14)70950-8. View

10.

Gagliotti C, Giordani S, Ciccarese V, Barozzi A, Giovinazzi A, Pietrantonio A . Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study. Am J Infect Control. 2014; 42(9):1006-8. DOI: 10.1016/j.ajic.2014.05.028. View

11.

Carlier M, Noe M, De Waele J, Stove V, G Verstraete A, Lipman J . Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother. 2013; 68(11):2600-8. DOI: 10.1093/jac/dkt240. View

12.

Popejoy M, Paterson D, Cloutier D, Huntington J, Miller B, Bliss C . Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2016; 72(1):268-272. DOI: 10.1093/jac/dkw374. View

13.

Retamar P, Lopez-Cerero L, Muniain M, Pascual A, Rodriguez-Bano J . Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013; 57(7):3402-4. PMC: 3697383. DOI: 10.1128/AAC.00135-13. View

14.

Donskey C . Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis. 2006; 43 Suppl 2:S62-9. DOI: 10.1086/504481. View

15.

Abdul-Aziz M, Lipman J, Akova M, Bassetti M, De Waele J, Dimopoulos G . Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit.... J Antimicrob Chemother. 2015; 71(1):196-207. DOI: 10.1093/jac/dkv288. View

16.

Lee N, Lee C, Huang W, Tsui K, Hsueh P, Ko W . Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2012; 56(4):488-95. DOI: 10.1093/cid/cis916. View

17.

Shotwell M, Nesbitt R, Madonia P, Gould E, Connor M, Salem C . Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT. Clin J Am Soc Nephrol. 2016; 11(8):1377-1383. PMC: 4974884. DOI: 10.2215/CJN.10260915. View

18.

Schwaber M, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y . Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2007; 52(3):1028-33. PMC: 2258527. DOI: 10.1128/AAC.01020-07. View

19.

Tsai H, Chen Y, Tang H, Huang C, Liao C, Chu F . Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014; 80(3):222-6. DOI: 10.1016/j.diagmicrobio.2014.07.006. View

20.

Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S . Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?. J Antimicrob Chemother. 2016; 71(4):1088-97. DOI: 10.1093/jac/dkv423. View